Ert Batten Brineura denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for ert batten brineura are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Quantity Limits to Brineura and How to Appeal Them

Cigna's pharmacy or medical benefit system may apply quantity limits to Brineura (cerliponase alfa) — typically reflecting the standard dosing regimen described in the FDA-approved prescribing label. A quantity-limit denial usually arises when the authorized quantity does not match what was prescribed, or when a dispensing or administration cycle falls outside the approved interval. For a biologic administered by a specialist in a clinical setting, quantity-limit denials are often driven by coding or scheduling mismatches rather than a genuine clinical dispute.

However, if a prescriber has determined that a patient's clinical circumstances require a dosing approach that differs from the standard regimen, that medical judgment can be the basis for a quantity-limit exception appeal.

## Federal Appeal Rights

Quantity-limit denials are adverse benefit determinations subject to appeal under ACA Section 2719 and ERISA Section 503. Internal appeal and independent external review rights apply. Because CLN2 disease is progressive and treatment interruptions or delays can accelerate neurological decline, a request for expedited review is appropriate whenever standard timelines would jeopardize the patient's health. External review by an IRO is available after internal exhaustion, generally within 4 months of the denial.

## Appeal Process and Timeline

1. Clarify the denial basis — determine whether the limit reflects an administrative mismatch (wrong quantity submitted vs. what the label describes) or a clinical dispute about appropriate dosing. 2. Administrative correction (if applicable) — if it is a billing or prior-authorization coding error, work with the specialty pharmacy or infusion center to correct and resubmit. 3. Quantity-limit exception appeal — if the prescriber believes the patient's needs differ from the standard regimen, submit a formal exception request with clinical justification. 4. External review — if the internal exception is denied, escalate to IRO review.

## Documentation to Gather

• Prescribing label reference: obtain the current FDA-approved Brineura prescribing label and confirm the dosing regimen described. If the prescribed quantity matches the label, cite this directly.
• Prescriber letter: explaining the clinical basis for the prescribed quantity, with reference to the patient's weight, age, disease stage, and any factors affecting dosing — without asserting specific mg figures in the appeal narrative; instead, attach the label and chart.
• Administration records: documentation from the infusion center or neurology clinic confirming the treatment schedule.
• Diagnosis and severity documentation: neurologist notes confirming active CLN2 disease and current treatment status.

## Criteria-Mapping Structure

Retrieve Cigna's quantity-limit policy for Brineura from the denial letter or Cigna's published coverage policies. Map the approved quantity limit to the FDA-approved prescribing label's standard regimen. If there is a discrepancy, document it explicitly. If the prescriber requires an exception to the standard quantity limit, address each of Cigna's exception criteria in turn, citing the specific chart findings and the prescribing label language that support the request.